[Pluto Pharmaceutical: Subsidiary received approval for marketing application for chemical raw material drug cefditoren pivoxil] On September 9, Prolu Pharmaceutical (000739.SZ) announced that the company's wholly-owned subsidiary Zhejiang Prodebon Pharmaceuticals received the "Notice of Approval for Marketing Application for Chemical API Cefditoren pivoxil" issued by the Food and Drug Administration. This drug is suitable for respiratory tract, urinary system, biliary tract, skin and soft tissue infections caused by sensitive bacteria. This approval marks that the product is qualified for domestic market sales, which will help expand the product pipeline and promote the development strategy of the refined raw material business, which has positive significance for the company's future development.